Clinical trials: Nutritional Deficiencies
Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at…
- Trial name
- NCT05652335
- Testing
- JNJ-79635322
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 180 people
- Sponsor
- Janssen Research & Development, LLC
Amyotrophic Lateral Sclerosis
A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
- Trial name
- NCT05039099
- Testing
- AP-101
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 73 people
- Sponsor
- AL-S Pharma
Malnutrition
Tolerance and Acceptability Evaluation of AYMES AMSTERDAM
To evaluate tolerance and acceptability of 'AMSTERDAM' in patients requiring supplementary oral nutritional support compared with currently available alternatives.
- Trial name
- NCT04700293
- Testing
- AYMES AMSTERDAM
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Aymes International Limited
Cardiac Amyloidosis
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
This study is an open-label study to evaluate and characterize test-retest reliability of [18F]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects.
- Trial name
- CATI (NCT06790394)
- Testing
- Florbetaben F18
- Where
- 2 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Lantheus Germany GmbH
Osteoporosis, Vitamin D Deficiency
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
The purpose of this study is to test the safety, tolerability and effectiveness of an investigational drug and dietary supplement to reduce the risk of vitamin D insufficiency and deficiency during the treatment of osteoporosis…
- Trial name
- NCT00092066
- Testing
- MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks
- Volunteers
- 717 people
- Sponsor
- Organon and Co
Alzheimer's Disease, Parkinson's Disease
Evaluation of a Diet in Patients With Senile Dementia
The most common symptoms associated to senile dementia disease are confusion about schedules, hyperactivity... In this sense, these patients have frequently poor nutrition, resulting in malnutrition problems or malnutrition high…
- Conditions
- Alzheimer's Disease, Parkinson's Disease, Senile Dementia
- Trial name
- SUPRESSI (NCT01192529)
- Testing
- Supressi. T-Diet plus Range, High Protein. T-Diet plus Range
- Where
- 3 sites in Spain
- Volunteers
- 184 people
- Sponsor
- Vegenat, S.A.
Alzheimer's Disease, Frontotemporal Dementia
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease…
- Trial name
- NCT01890343
- Testing
- florbetapir 18F, 18F-FDG
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Nutritional Deficiency
Dose-response Enteral Citrulline for Normal Healthy Volunteers and Surgery Patients
To determine the level of citrulline to produce a given amount of arginine in healthy volunteers and surgical patients. Arginine-related amino acids are expected to increase as a result of increased substrate provided by…
- Trial name
- NCT00950976
- Testing
- citrulline, Lemonade
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Malnutrition
EnergieShake 1.5kcal Complete Acceptability and Tolerance Study
This open-label, prospective, controlled intervention study involves evaluating tolerance and acceptability of an Oral Nutrition Supplement (ONS; EnergieShake® 1.5 kcal Complete drink) in 18 adult patients who are already taking…
- Trial name
- NCT02796482
- Testing
- EnergieShake 1.5kcal Complete
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Anaiah Healthcare Pvt Ltd
Amyotrophic Lateral Sclerosis
Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)
The study will evaluate the safety, tolerability and therapeutic effects of transplantation of escalating doses of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), in patients…
- Trial name
- NCT01777646
- Testing
- MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
- Where
- Israel
- Volunteers
- 14 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis
Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)
This was a 2-part study of dexpramipexole in patients with ALS. Part 1 was a randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, and clinical effects of oral administration of 3 dosage levels…
- Trial name
- CL201 (NCT00647296)
- Testing
- Dexpramipexole 50 mg/day, Dexpramipexole 150 mg/day, Dexpramipexole 300 mg/day
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- Knopp Biosciences
Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial of LMTM continued access to therapy and to evaluate the long-term safety of LMTM.
- Trial name
- NCT02245568
- Testing
- LMTM
- Where
- 135 sites in United States, Australia and 15 more
- Volunteers
- 913 people
- Sponsor
- TauRx Therapeutics Ltd
Amyloidogenic Transthyretin (ATTR) Amyloidosis
A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
A Phase 1, open-label study of intravenous (IV) PRX004 as a single agent in subjects with hereditary amyloid transthyretin (hATTR) amyloidosis. The study will consist of 3 phases and will enroll up to a total of 36 subjects.
- Trial name
- NCT03336580
- Testing
- PRX004
- Where
- 7 sites in United States, Portugal and 2 more
- Volunteers
- 21 people
- Sponsor
- Prothena Biosciences Limited
Malnutrition, Child, Malnutrition
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipid.
- Conditions
- Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
- Trial name
- NCT06049680
- Testing
- SMOFlipid® (lipid injectable emulsion)
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Fresenius Kabi
Amyotrophic Lateral Sclerosis
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS.
- Trial name
- NCT04516096
- Testing
- AMX0035
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects…
- Trial name
- NCT02478450
- Testing
- Q-Cells
- Volunteers
- 30 people
- Sponsor
- Q Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.
- Trial name
- NCT05299658
- Testing
- CNMAu8
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Clene Nanomedicine
Dietary Deficiency, Sodium
Cross-sectional, Non-randomized Observational Study to Assess the Frequency of Reduced Sodium Intake in the Primary Care Setting - LAXAP
This study is a cross-sectional epidemiological, observational study. It would be carried out in primary health care sites. The purpose of this study is estimating the percentage of patients aged 60 years or older who suffer from…
- Trial name
- LAXAP (NCT06121583)
- Where
- 14 sites in Spain
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- Casen Recordati S.L.
Amyotrophic Lateral Sclerosis (ALS)
A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)
The objective of this study is to investigate the long term safety of ALS patients taking ONO-2506PO.
- Trial name
- NCT00694941
- Testing
- ONO-2506PO
- Where
- 25 sites in Belgium, France and 5 more
- Volunteers
- 15 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis
Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
This is a first-in-human trial of spinal derived stem cells transplanted into the spinal cord of patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- ALS (NCT01348451)
- Testing
- surgical implantation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Neuralstem Inc.